⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IFRX News
InflaRx N.V. Common Stock
InflaRx to Report First Quarter 2026 Results on May 7, 2026
globenewswire.com
IFRX
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
globenewswire.com
IFRX
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
globenewswire.com
IFRX
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
globenewswire.com
IFRX
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
IFRX
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
globenewswire.com
IFRX
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
globenewswire.com
IFRX
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
globenewswire.com
IFRX
InflaRx to Report Full Year 2025 Results on March 19, 2026
globenewswire.com
IFRX
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
globenewswire.com
IFRX